Article citationsMore>>

Sakaida, I., Terai, S., Kurosaki, M., et al. (2017) Effectiveness and Safety of Tolvaptan in Liver Cirrhosis Patients with Edema: Interim Results of Post-Marketing Surveillance of Tolvaptan in Liver Cirrhosis (START Study). Hepatology Research, 47, 1137-1146.
https://doi.org/10.1111/hepr.12852

has been cited by the following article:

• TITLE: The Evaluation of Tolvaptan Therapy and Long-Term Prognosis in Hepatocellular Carcinoma with Refractory Ascites

  AUTHORS: Masaaki Shimada, Hiroaki Iwase, Noboru Hirashima, Masashi Saito, Hisashi Kondo, Noboru Urata, Satoshi Unita, Takashi Kondo, Daiki Tanaka

  KEYWORDS: Tolvaptan, Hepatic Ascites, Sarcopenia, Loop Diuretics, Long-Term Prognosis

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.8 No.2, February 13, 2018

  ABSTRACT: We investigated Tolvaptan efficacy and long-term prognosis with focus on nutrition in 20 patients with refractory hepatic ascites in hepatocellular carcinoma (HCC). Bloating improved in 55% of patients, as determined using a Japanese version of the Support Team Assessment Schedule. Nutritional status improved with Tolvaptan treatment, based on the Controlling Nutritional Status score and Onodera’s prognostic nutritional index. Long-term prognosis was better in responders than in non-responders (mean survival time: 308 days vs. 97 days, p = 0.031). Tolvaptan was even effective in many patients with HCC, with additional improvement in long-term prognosis expected with improvement in the nutritional status.